Congratulations

  • Dr. David Collister (Scientific Operations and Executive Committee member) for his project – DIalysis Symptom COntrol- Pruritis Outcome Trial (DISCO-POT)

 

  • Dr. Clara Bohm (Scientific Operations and Executive Committee member) for her project – Trial of interdialytic cycling as kidney exercise rehabilitation for cardiac stunning in hemodialysis (TICKER_HD)

 

  • Dr. Claudio Rigatto for his project – A pragmatic randomized controlled trial of a CKD specific telemonitoring platform to minimize adverse outcomes in high risk CKD patients

 

We look forward to sharing the results with this community in the future.

New committee members needed!

The Capacity Building Committee and Communications and Engagement Committee are looking for additional members. These committees meet monthly for 1 hour to discuss ideas and move forward initiatives.

 

The Capacity Building Committee is focused on training and development of CNTN membership and the mentorship of new investigators and patient partners. Their mandate is to increase the number of people and resources available to conduct clinical trials in Canada and to increase the number of research ideas or questions developed by both patients and physicians.

 

 

The Communications and Engagement Committee’s mission is to increase the exposure of CNTN to the nephrology community across Canada thereby increasing membership to facilitate more collaboration with academic and non-academic sites across Canada and keeping that community informed about what is happening in the research community.

 

Email the CNTN project manager, Alicia at amurdoch@cansolveckd.ca, if you have questions or would like to join the committee.

How Canada can better embed randomized trials into clinical care

In the most recent issue of the Canadian Medical Association Journal, Drs. Srinivas MurthyRobert A. Fowler and Andreas Laupacis wrote an editorial about how the speed with which the UK executed the nation-wide priority-driven RECOVERY trial is not currently possible in Canada. 

From the editorial: “Those who manage and fund Canada’s health care systems need to view high-priority trials as an integral part of clinical care and to provide adequate and stable infrastructure funding, thus avoiding the current time-consuming and expensive process of developing separate data-sharing agreements and contracts with many hospitals and organizations. ”

You view the editorial online or download a PDF copy.

The Do’s and Don’ts of Patient Engagement

Patient engagement is a relatively new way of conducting research in Canada and many researchers are probably still wondering how to do it well. Dr. Simon Hatcher and his team at the Ottawa Hospital developed a graphic novel style tip sheet, “Top 10 Recommendations for Researchers Working with Lived Experience Partners“.

The comic was created by people with lived experience of suicide at the REFLECT research forum which brought together patients and caregivers as well as suicide prevention researchers, trainees and policy-makers.

The top 10 recommendations are:

  1. Use common and clear language
  2. Allow for customization to patient partner’s needs. Be flexible.
  3. Be authentic in the approach to patient-oriented research. Avoid tokenism.
  4. Define roles. Invite and acknowledge everyone’s contributions.
  5. Balance power dynamics.
  6. Invite patient partners to do more than what they are recruited for.
  7. Compensate fairly and as a matter of course. Reimburse expenses.
  8. Build relationships through honesty and trust.
  9. Ensure governance through integrity and accountability.
  10. Establish and encourage continuous communication and feedback.

Feasibility study into LPHS

Dr. Bhanu Prasad and his research team are conducting a feasibility study of a randomized controlled trial investigating renal denervation as a possible treatment option in patients with Loin Pain Hematuria Syndrome (LPHS). Dr. Prasad presented this study at the CNTN meeting in November 2019 in Washington, D.C and we look forward to hearing more about the study at future CNTN meetings.

Loin Pain Hematuria Syndrome (LPHS) is a poorly understood clinical condition characterized by severe pain localized to the kidney but in the absence of identifiable urinary tract disease. Case reports/series have shown renal denervation via catheter-based radiofrequency ablation to be an effective therapeutic option for the treatment of LPHS. To determine whether catheter-based renal denervation is a meaningful addition to the treatment options in these often difficult to treat LPHS patients, a randomized clinical trial is needed. Prior to conducting a definitive trial that focuses on patient outcomes, ensuring the feasibility of undertaking such a trial is required. As such, we will conduct a single-centre randomized control feasibility trial designed to determine viability and provide framework and direction for a larger trial.

The research team will conduct a double-blinded, parallel-group, partial crossover, sham-controlled, randomized feasibility trial on 10 LPHS patients at the Regina General Hospital, Saskatchewan. Participants will be randomized into either renal denervation (treatment group) or a sham treatment (control group). Data (pain, quality of life, mood, disability) will be collected from both groups at baseline, 6 weeks, 3 and 6 months after the intervention. After the initial 6-month follow-up is over, the participants who received the sham procedure will cross over into the treatment group and will be followed for an additional 6 months in the same manner as the treatment group.

The lessons learnt from this trial will lay the framework and direction for conducting a multi-site randomized controlled trial involving a larger cohort of patients.

CSN e-Poster available for viewing

On behalf of the network, an abstract was submitted and accept for the CSN annual general meeting entitled, “A New Vision for Nephrology Trials in Canada” . The meeting was cancelled but the poster was submitted and can be found on the Can-SOLVE CKD website and the CSN poster website.

As part of the Can-SOLVE CKD virtual network update, a short 7-minute presentation was given by Alicia Murdoch, the CNTN coordinator. You can view the recording of the presentation here.

CNTN represented on CSN Board of Directors

The Canadian Society of Nephrology (CSN) announced their new president and board of directors today. We are pleased to share that 3 CNTN committee members are on the new board.

Rita Suri, member of the Scientific Operations and Executive committees, will be the chair of the CSN Scientific committee.

 

 

 

Amber Molnar, co-chair of the Communications and Engagement committee, will be representing the province of Ontario on the CSN board.

 

 

 

Bhanu Prasad, member of the Communications and Engagement committee, will be the chair of the CSN Community Nephrology committee.

 

 

 

Congratulations to everyone who was elected to the board.

COVID-19 Related Trials Listing

Below is a list of COVID-19 specific study websites and websites with study lists.  As the number of COVID-19 related studies increases, we will do our best to keep this page updated.

  • Health care workers and those living with COVID-19 positive people in Alberta, Manitoba and Quebec are eligible to participate in a trial of post-exposure prophylaxis at http://covid-19research.ca
  • COVID-19-COS project brings together patients, the public and health professionals to identify, prioritise and agree on the most important outcomes for research in COVID-19. Round 1 is planned to close on April 10, visit https://www.covid-19-cos.org/ to participate.
  • COVID-19 Resources Canada lists ongoing Canadian trials that can be sorted by Principal Investigator, Institution or Research Category.

Active Canadian trials listed on ClinicalTrials.gov can be found here.

COVID-19 Trial Management Resources

As the COVID-19 pandemic continues, most hospitals have halted all non-emergency visits, greatly affecting the conduct of clinical trials. Below are links to both Health Canada and the US Food and Drug Administration (FDA) guidance on the management of clinical trials during this time, as well as various Canadian research organizations. This post will be updated as more resources come to our attention.

We are working to collect a list of trial resources to help trialist overcome challenges and keep their research program moving forward. If you have had success or suggestions that you can share, please email amurdoch@cansolveckd.ca.

Canadian Institutes for Health Research FAQs on Impact of COVID-19 – https://cihr-irsc.gc.ca/e/51917.html#faq

Health Canada Guidance on Management of Clinical Trials during the COVID-19 pandemic – https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/management-clinical-trials-during-covid-19-pandemic.html

US FDA Guidance for Clinical Trials during COVID-19 – https://www.fda.gov/media/136238/download

COVID-19 Resources Canada – https://covid19resources.ca/activeresearch.html

Clinical Trials Ontario –  https://www.ctontario.ca/covid-19-clinical-trial-resources/

Clinical Trials BC – https://www.clinicaltrialsbc.ca/updates-for-clinical-trials-bc-regarding-covid-19/

Canadian Institute of Health Information (CIHI)  – https://www.cihi.ca/en/covid-19-resources